• GLP-1 (9-36) Amide: Evidence and Scope

  2026-10-15

  APExBIO lists GLP-1 (9-36) amide, SKU B5404, as a peptide antagonist at the human GLP-1 receptor. The available documentation supports a catalog-level identity and a conceptual role in GLP-1 receptor signaling research, but it does not provide identity-matched primary-study data, quantitative pharmacology, assay outcomes, or independent validation of selectivity and functional performance.

• GLP-1 (9-36) Amide: Evidence Boundaries

  2026-10-15

  APExBIO describes GLP-1 (9-36) amide as a peptide antagonist of the human GLP-1 receptor for receptor-signaling and metabolic research. The available product information supports a cautious identity and scope overview, but provides no identity-matched study data establishing potency, selectivity, assay performance, or clinical relevance.

• Canagliflozin and Kidney Mitochondrial Remodeling

  2026-10-14

  A 2025 mouse study associated canagliflozin with improved proximal-tubule mitochondrial structure and bioenergetics in hypertensive–diabetic males, while female mice showed a more limited structural response. The findings support mitochondrial remodeling as a plausible component of SGLT2 inhibitor kidney protection, but they do not establish a direct mitochondrial target or separate drug-specific effects from glucose normalization.

• SHC-1, CFTR Trafficking, and Model Context

  2026-10-14

  Barros et al. report that MAPK/SHC-1-associated CFTR internalization is detectable across airway and intestinal epithelial models, but pharmacological increases in surface CFTR were restricted to CFBE cells and were not selective for CFTR. The findings support a conserved trafficking mechanism while highlighting substantial cell-context limitations.

• Reelin Signaling as a Gate for Ketamine Plasticity

  2026-10-13

  A 2021 PNAS mouse study examined whether Reelin–Apoer2–Src family kinase signaling is required for ketamine-associated hippocampal plasticity and antidepressant-relevant behavioral effects. The findings support a permissive role for intact baseline NMDA receptor function, while leaving human treatment response and clinical translation unresolved.

• Canagliflozin and Proximal Tubule Mitochondria

  2026-10-13

  A 2025 mouse study examined whether Canagliflozin-related kidney protection is associated with mitochondrial remodeling in proximal tubular cells. The reported effects were stronger in males than females, supporting a mechanistic association but not establishing causality or clinical applicability.

• How Early Pheromone Signals Shape Worm Neurodegeneration

  2026-10-12

  Peng et al. report that early exposure to two C. elegans pheromones can remodel neuronal signaling and accelerate later neurodegeneration through coordinated sensory, interneuron, insulin-like, and autophagy-related pathways. The findings offer a mechanistic model for environmental influence on proteostasis, but their relevance to human disease remains limited by the organism, developmental context, and model-specific evidence.

• Spatially Concentrated Base Editing in Oligodendrocytes

  2026-10-12

  A 2026 Nucleic Acids Research study reports that spatially concentrating adenine base-editing components can improve correction of the PLP1 A243V mutation in oligodendrocytes while reducing transcriptome-wide RNA off-target effects. The findings are promising but remain preclinical, and the supplied evidence does not establish long-term safety, durability, or clinical efficacy.

• Clozapine: Mechanisms in Schizophrenia Research

  2026-10-10

  Clozapine is an atypical antipsychotic medication with broad serotonin and dopamine receptor activity. Product-dossier evidence links it to ERK1/2 signaling activation and hepatotoxicity studies, while a separate mouse study identifies GABRE regulation as a mechanism associated with magnetic-stimulation effects rather than clozapine treatment.

• MK 0893: Evidence on GCGR Antagonism

  2026-10-09

  MK 0893 is a research-stage glucagon receptor antagonist used to examine GCGR signaling, cAMP responses, and glucagon-driven glucose regulation. This overview separates supplier-reported pharmacology from findings in a 2015 medicinal chemistry study, emphasizing evidence strength, conceptual applications, and limitations relevant to type 2 diabetes research.

• CFTRinh-172: Reading CFTR Biology Without Overreach

  2026-10-09

  CFTRinh-172 is a selective CFTR inhibitor that can clarify whether epithelial phenotypes reflect channel activity or membrane abundance. This article interprets its value through a model-validity framework informed by recent cross-cell research on CFTR trafficking.

• Ions Improve CPP Nucleic Acid Delivery: What the Study Shows

  2026-10-08

  The reference study shows that inorganic ions can reshape the physicochemical properties of cell-penetrating peptide–nucleic acid nanoparticles and improve productive intracellular delivery. Its main contribution is to separate nanoparticle internalization from downstream delivery performance, indicating that ion supplementation primarily supports endosomal escape rather than simply increasing cellular entry.

• Halazone: Evidence, Applications, and Limitations

  2026-10-07

  Halazone is an organic chloramine compound described as a water disinfection agent and studied as an electrophysiological probe. The strongest supplied evidence comes from a 1986 voltage-clamp study in frog myelinated nerve fibers, where Halazone and hypochlorous acid disrupted sodium-current inactivation. Supplier claims support research context but do not independently establish real-world disinfection performance, clinical safety, resistance outcomes, or a defined molecular target. This overview separates reported findings from interpretation and identifies key applicability boundaries.

• Elobixibat Hydrate: Evidence and Limits

  2026-10-07

  A source-grounded overview of Elobixibat hydrate, the evidence behind its proposed IBAT mechanism, and why rapakinin findings cannot validate clinical or metabolic claims.

• CX-4945: Interpreting CK2 Evidence in Cancer

  2026-10-06

  CX-4945 (Silmitasertib) is a selective CK2 inhibitor whose value in cancer research depends on how biochemical, cellular, genetic, and in vivo evidence are integrated. This article examines the ECE-1c–CK2 axis in lung cancer and defines what the available findings do—and do not—establish.

7960 records 1/531 page Next 12345 下5页 Last page